Blog
About

1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Patient-Focused Drug Development: A New Direction for Collaboration.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Patient-Focused Drug Development (PFDD) is a new initiative from the Food and Drug Administration (FDA) intended to bring patient perspectives into an earlier stage of product development. The goal is that patients will be able to provide context for benefit-risk assessments and input to review divisions, and also aid in the development of new assessment tools, study endpoints, and risk communications. This paper provides a summary on what is known to date about FDA's PFDD initiative and describes implications for patients, researchers, payers, and the biopharmaceutical industry. It also provides a roadmap for stakeholders to consider in defining their role in and in shaping PFDD's direction, and for expanding PFDD principles to conditions beyond the current 20 under FDA consideration.

          Related collections

          Author and article information

          Journal
          Med Care
          Medical care
          1537-1948
          0025-7079
          Jan 2015
          : 53
          : 1
          Affiliations
          [1 ] *Department of Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, MD †LORA Group LLC, Royal Oak, MD ‡Epstein Health LLC, Woodcliff Lake, NJ.
          00005650-201501000-00003
          10.1097/MLR.0000000000000273
          25494232

          Comments

          Comment on this article